Eli Lilly (LLY) intends to turn India into a hub for its global supply chain, Rishika Sadam and Kashish Tandon of Reuters reports, citing comments made by a senior executive at the company. Sales of Mounjaro have doubled within months of its launch in the country and has become a top-selling medicine by value. Eli Lilly currently does not operate its own manufacturing facility in India, but plans to export locally produced drugs to markets across the world as part of its supply network.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill
- IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio
- Eli Lilly reports Phase 3 LIBRETTO-432 study of Retevmo met primary endpoint
- Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia
- Eli Lilly has built $1.5B worth of inventory of orforglipron, Reuters says